Sixty adult patients with FLT3-mutant AML after undergoing allo-HCT in first remission were randomized to receive either standard of care (n = 14) or midostaurin 50 mg twice daily for 12 months (n = 16). Here, FLT3 is linked to acute myeloid leukemia.